Genomic landscape of metastatic breast cancer (MBC) patients with methylthioadenosine phosphorylase (<i>MTAP</i>) loss

Abstract

<i>MTAP</i> loss in MBC has distinct clinical features with genomic alterations (GA) affecting both targeted and immunotherapies. Further efforts are necessary to identify alternative means of targeting PRMT5 and MTA2 in <i>MTAP</i>-ve cancers to benefit from the high-MTA environment of <i>MTAP</i>-deficient cancers.